Impact of prior CAR T-cell therapy on mosunetuzumab efficacy in patients with relapsed or refractory B-cell lymphomas

Authors: Elise A. Chong, Elicia Penuel, Ellen B. Napier, Rachel K. Lundberg, Lihua E. Budde, Mazyar Shadman, Matthew J. Matasar, Nancy L. Bartlett, Ian W. Flinn, Francesc Bosch, Keith Fay, Andre Goy, Anita Kumar, Loretta J. Nastoupil, Michael C. Wei, Mei Wu, Shen Yin, Joseph A. Fraietta, Emeline R. Chong, Stephen J. Schuster

Source: Blood Advances, Vol 9, Iss 4, Pp 696-703 (2025)

Subject Terms: Specialties of internal medicine, RC581-951

File Description: electronic resource

Relation: http://www.sciencedirect.com/science/article/pii/S2473952924006724; https://doaj.org/toc/2473-9529

Access URL: https://doaj.org/article/ccaea24960464786b8012cda2e6aebdb

Evaluation of bleeding risk in patients who received pirtobrutinib in the presence or absence of antithrombotic therapy

Authors: Nicole Lamanna, Constantine S. Tam, Jennifer A. Woyach, Alvaro J. Alencar, M. Lia Palomba, Pier Luigi Zinzani, Ian W. Flinn, Bita Fakhri, Jonathon B. Cohen, Arrin Kontos, Heiko Konig, Amy S. Ruppert, Anindya Chatterjee, Richard Sizelove, Livia Compte, Donald E. Tsai, Wojciech Jurczak

Source: eJHaem, Vol 5, Iss 5, Pp 929-939 (2024)

Subject Terms: antithrombotic therapy, B‐cell cancers, bleeding, Bruton tyrosine kinase inhibitor, pirtobrutinib, Diseases of the blood and blood-forming organs, RC633-647.5

File Description: electronic resource

Relation: https://doaj.org/toc/2688-6146

Access URL: https://doaj.org/article/82cd9c8755ab4351873ea8a263b45176

The phase III DUO trial of PI3K inhibitor duvelisib versus ofatumumab in relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma: final analysis including overall survival

Authors: Alexey V. Danilov, Ian W. Flinn, Matthew S. Davids, Beth Gregory, Ohad Bentur, David Sidransky, Jennifer R. Brown

Source: Haematologica, Vol 999, Iss 1 (2024)

Subject Terms: Diseases of the blood and blood-forming organs, RC633-647.5

File Description: electronic resource

Relation: https://haematologica.org/article/view/11624; https://doaj.org/toc/0390-6078; https://doaj.org/toc/1592-8721

Access URL: https://doaj.org/article/a78b1ed440224fbeb6f51259c422cfb9

Genomic landscape of patients in a phase II study of zanubrutinib in ibrutinib- and/or acalabrutinib-intolerant patients with B-cell malignancies

Authors: Linlin Xu, Mazyar Shadman, Ian W. Flinn, Moshe Y. Levy, Ryan Porter, John M. Burke, Syed F. Zafar, Jennifer L. Cultrera, Jamal Misleh, Edwin C. Kingsley, Habte A. Yimer, Benjamin Freeman, Arvind Chaudhry, Praveen K. Tumula, Mitul D. Gandhi, Rocco Crescenzo, Kunthel By, Aileen Cohen, Dih-Yih Chen, Adam Idoine, Sudhir Manda, Jeff P. Sharman, Vanitha Ramakrishnan

Source: Haematologica, Vol 999, Iss 1 (2024)

Subject Terms: Diseases of the blood and blood-forming organs, RC633-647.5

File Description: electronic resource

Relation: https://haematologica.org/article/view/11417; https://doaj.org/toc/0390-6078; https://doaj.org/toc/1592-8721

Access URL: https://doaj.org/article/1c2ee5ac31c545ed8f557348df39cf33

PB2319: ZUMA-23: A GLOBAL, PHASE 3, RANDOMIZED CONTROLLED STUDY OF AXICABTAGENE CILOLEUCEL VERSUS STANDARD OF CARE AS FIRST-LINE THERAPY IN PATIENTS WITH HIGH-RISK LARGE B-CELL LYMPHOMA

Authors: Jason Westin, Caron Jacobson, Julio C Chavez, Anna Sureda, Franck Morschhauser, Bertram Glass, Michael Dickinson, Andrew J. Davies, Ian W. Flinn, David Maloney, Martine Chamuleau, Michael Tees, Allen Xue, Shilpa Shahani, Olga Nikolajeva, Janet Kang, Aida Kaplan, Marco Schupp, Harry Miao, Elizabeth Shima Rich

Source: HemaSphere, Vol 7, p e3278692 (2023)

Subject Terms: Diseases of the blood and blood-forming organs, RC633-647.5

File Description: electronic resource

Relation: http://journals.lww.com/10.1097/01.HS9.0000975996.32786.92; https://doaj.org/toc/2572-9241

Access URL: https://doaj.org/article/f25c7cb01f0949d49598ffa2e49b37f6

P633: UPDATED SAFETY AND EFFICACY RESULTS OF ZANUBRUTINIB IN PATIENTS WITH B-CELL MALIGNANCIES WHO ARE INTOLERANT OF IBRUTINIB AND/OR ACALABRUTINIB

Authors: Mazyar Shadman, Moshe Y. Levy, Ryan Porter, John M. Burke, Jennifer L. Cultrera, Jamal Misleh, Jeff Sharman, Syed F. Zafar, Kunthel By, Aileen Cohen, Rocco Crescenzo, Adam Idoine, Ian W. Flinn

Source: HemaSphere, Vol 7, p e70152b3 (2023)

Subject Terms: Diseases of the blood and blood-forming organs, RC633-647.5

File Description: electronic resource

Relation: http://journals.lww.com/10.1097/01.HS9.0000969436.70152.b3; https://doaj.org/toc/2572-9241

Access URL: https://doaj.org/article/1ca72ba9a96d495e95c753f8dc08b616

P627: LONG-TERM OUTCOMES WITH CONTINUOUS IBRUTINIB IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA: ANALYSIS OF TIME TO PROGRESSION

Authors: Thomas Kipps, Carolyn Owen, Ian W. Flinn, Paul M. Barr, Alessandra Tedeschi, Richard Greil, Edith Szafer-Glusman, Hsin-Hui Huang, Lynne Neumayr, Chris Abbazio, Tait Shanafelt

Source: HemaSphere, Vol 7, p e4326761 (2023)

Subject Terms: Diseases of the blood and blood-forming organs, RC633-647.5

File Description: electronic resource

Relation: http://journals.lww.com/10.1097/01.HS9.0000969412.43267.61; https://doaj.org/toc/2572-9241

Access URL: https://doaj.org/article/c10f8872813c4deca3ad7def8184f141

P639: ZANUBRUTINIB (ZANU) VS BENDAMUSTINE + RITUXIMAB (BR) IN PATIENTS (PTS) WITH TREATMENT-NAÏVE CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA (CLL/SLL): EXTENDED FOLLOW-UP OF THE SEQUOIA STUDY

Authors: Talha Munir, Mazyar Shadman, Tadeusz Robak, Jennifer R. Brown, Brad Kahl, Paolo Ghia, Krzysztof Giannopoulos, Martin Simkovic, Anders Österberg, Luca Laurenti, Patricia Walker, Stephen Opat, Hanna Ciepluch, Richard Greil, Merit Hanna, Monica Tani, Marek Trneny, Danielle M. Brander, Ian W. Flinn, Sebastian Grosicki, Emma Verner, Alessandra Tedeschi, Sophie De Guibert, Gayane Tumyan, Kamel Laribi, Jose Antonio Garcia Marco, Jianyong LI, Tian Tian, Vanitha Ramakrishnan, Yu Liu, Andy Szeto, Jason Paik, Aileen Cohen, Constantine Tam, Wojciech Jurczak

Source: HemaSphere, Vol 7, p e15364af (2023)

Subject Terms: Diseases of the blood and blood-forming organs, RC633-647.5

File Description: electronic resource

Relation: http://journals.lww.com/10.1097/01.HS9.0000969460.15364.af; https://doaj.org/toc/2572-9241

Access URL: https://doaj.org/article/7091e26a2653416c8b09960a458575a4

PB2346: ZUMA-24: A PHASE 2, OPEN-LABEL, MULTICENTER STUDY OF AXICABTAGENE CILOLEUCEL IN PATIENTS WITH RELAPSED/REFRACTORY LARGE B-CELL LYMPHOMA GIVEN WITH CORTICOSTEROIDS IN THE OUTPATIENT SETTING

Authors: Lori Leslie, Michael Tees, Ian W. Flinn, Tulio Rodriguez, John H. Baird, Abhinav Deol, Monica Mead, Carlos Bachier, Aaron P. Rapoport, Brian Mcclune, Daanish Hoda, Miguel-Angel Perales, Yan Zheng, Simone Filosto, Madison Davis, Harry Miao, Jenny J. Kim, Olalekan O. Oluwole

Source: HemaSphere, Vol 7, p e50042ff (2023)

Subject Terms: Diseases of the blood and blood-forming organs, RC633-647.5

File Description: electronic resource

Relation: http://journals.lww.com/10.1097/01.HS9.0000976104.50042.ff; https://doaj.org/toc/2572-9241

Access URL: https://doaj.org/article/cf51f2eb81ef4620b604ac78295b8d69

P579: SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PRELIMINARY ANTITUMOR ACTIVITY OF AZD5991 IN RELAPSED/ REFRACTORY HEMATOLOGIC MALIGNANCIES: A PHASE 1 FIRST-IN-HUMAN STUDY

Authors: Pinkal Desai, Sagar Lonial, Amanda Cashen, Manali Kamdar, James S. Blachly, Ian W. Flinn, Susan O’brien, Jacqueline Garcia, Neha Korde, Javid Moslehi, Margaret Wey, Patricia Cheung, Shringi Sharma, Damilola Olabode, Hong Chen, Firasath Ali Syed, Mary Liu, Jamal Saeh, Raoul Tibes, Marcio Andrade, Tapan Kadia

Source: HemaSphere, Vol 7, p e98838e7 (2023)

Subject Terms: Diseases of the blood and blood-forming organs, RC633-647.5

File Description: electronic resource

Relation: http://journals.lww.com/10.1097/01.HS9.0000969220.98838.e7; https://doaj.org/toc/2572-9241

Access URL: https://doaj.org/article/d5c07de1c1104e7abf60a32c2df2ca80

P628: UPDATED ANALYSIS OF BELLWAVE-001: A PHASE 1/2 OPEN-LABEL DOSE-EXPANSION STUDY OF THE EFFICACY AND SAFETY OF NEMTABRUTINIB FOR THE TREATMENT OF B-CELL MALIGNANCIES

Authors: Jennifer Woyach, Ian W. Flinn, Farrukh Awan, Herbert Eradat, Danielle M. Brander, Michael Tees, Sameer Parikh, Tycel Phillips, Razi Ghori, Ima Paydar, Mohammed Z. H. Farooqui, John C. Byrd, Deborah Stephens

Source: HemaSphere, Vol 7, p e7809236 (2023)

Subject Terms: Diseases of the blood and blood-forming organs, RC633-647.5

File Description: electronic resource

Relation: http://journals.lww.com/10.1097/01.HS9.0000969416.78092.36; https://doaj.org/toc/2572-9241

Access URL: https://doaj.org/article/69bf151243aa40aea67348ac1c9c5069

P1107: ZUMA-22: A PHASE 3, RANDOMIZED CONTROLLED STUDY OF AXICABTAGENE CILOLEUCEL VERSUS STANDARD-OF-CARE THERAPY IN PATIENTS WITH RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA

Authors: Ian W. Flinn, Caron Jacobson, Loretta J. Nastoupil, Franck Morschhauser, Andrew J. Davies, Christian Buske, Paolo Corradini, Armando Lopez-Guillermo, Ran Reshef, Vinod Parameswaran, Alison Sehgal, Michael Tees, Christine Lui, Wei Xue, Sara Beygi, Nikolay Grechko, Pisita Bolsue, Alessandro Giovanetti, Christina To, Myrna Nahas

Source: HemaSphere, Vol 7, p e6350662 (2023)

Subject Terms: Diseases of the blood and blood-forming organs, RC633-647.5

File Description: electronic resource

Relation: http://journals.lww.com/10.1097/01.HS9.0000971324.63506.62; https://doaj.org/toc/2572-9241

Access URL: https://doaj.org/article/ef44d6a08f2940c4843d4ce92bfe510e

P1064: BRENTUXIMAB VEDOTIN, NIVOLUMAB, DOXORUBICIN, AND DACARBAZINE FOR ADVANCED STAGE CLASSICAL HODGKIN LYMPHOMA: UPDATED EFFICACY AND SAFETY RESULTS FROM THE SINGLE ARM PHASE 2 STUDY

Authors: Chris Yasenchak, Ian W. Flinn, Jason Melear, Rod Ramchandren, Judah Friedman, John M. Burke, Yuliya Linhares, Paul Gonzales, Mihir Raval, Rangaswamy Chintapatla, Tatyana A. Feldman, Habte Yimer, Miguel Islas-Ohlmayer, Asad Dean, Vishal Rana, Mitul D. Gandhi, John Renshaw, Linda Ho, Michelle Fanale, Wenchuan Guo, Hun Ju Lee

Source: HemaSphere, Vol 7, p e5881312 (2023)

Subject Terms: Diseases of the blood and blood-forming organs, RC633-647.5

File Description: electronic resource

Relation: http://journals.lww.com/10.1097/01.HS9.0000971152.58813.12; https://doaj.org/toc/2572-9241

Access URL: https://doaj.org/article/6e8ef5b43868466087976545b54a69df

Phase Ib study of avadomide (CC‐122) in combination with rituximab in patients with relapsed/refractory diffuse large B‐cell lymphoma and follicular lymphoma

Authors: Loretta J. Nastoupil, John Kuruvilla, Julio C. Chavez, Fontanet Bijou, Thomas E. Witzig, Armando Santoro, Ian W. Flinn, Carola Boccomini, Vaishalee P. Kenkre, Paolo Corradini, Iris Isufi, David J. Andorsky, Leonard M. Klein, Daniel R. Greenwald, Randeep Sangha, Frank Shen, Patrick Hagner, Yan Li, Juergen Dobmeyer, Nian Gong, Shailaja Uttamsingh, Michael Pourdehnad, Vincent Ribrag

Source: eJHaem, Vol 3, Iss 2, Pp 394-405 (2022)

Subject Terms: avadomide, CELMoD, diffuse large B‐cell lymphoma, follicular lymphoma, Diseases of the blood and blood-forming organs, RC633-647.5

File Description: electronic resource

Relation: https://doaj.org/toc/2688-6146

Access URL: https://doaj.org/article/893d9f4d49df48ae90782ee3c1a4ed6c

Phase Ib study of combinations of avadomide (CC‐122), CC‐223, CC‐292, and rituximab in patients with relapsed/refractory diffuse large B‐cell lymphoma

Authors: Vincent Ribrag, Julio C. Chavez, Carola Boccomini, Jason Kaplan, Jason C. Chandler, Armando Santoro, Paolo Corradini, Ian W. Flinn, Ranjana Advani, Philippe A. Cassier, Randeep Sangha, Vaishalee P. Kenkre, Iris Isufi, Shailaja Uttamsingh, Patrick R. Hagner, Anita K. Gandhi, Frank Shen, Sophie Michelliza, Harald Haeske, Kristen Hege, Michael Pourdehnad, John Kuruvilla

Source: eJHaem, Vol 3, Iss 1, Pp 139-153 (2022)

Subject Terms: new drug development, non‐Hodgkin lymphoma, phase 1 clinical trials, Diseases of the blood and blood-forming organs, RC633-647.5

File Description: electronic resource

Relation: https://doaj.org/toc/2688-6146

Access URL: https://doaj.org/article/96c484da7911405ebd05aa9e00d581f2

First-line treatment of chronic lymphocytic leukemia with ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab: final analysis of the randomized, phase III iLLUMINATE trial

Authors: Carol Moreno, Richard Greil, Fatih Demirkan, Alessandra Tedeschi, Bertrand Anz, Loree Larratt, Martin Simkovic, Jan Novak, Vladimir Strugov, Devinder Gill, John G. Gribben, Kevin Kwei, Sandra Dai, Emily Hsu, James P. Dean, Ian W. Flinn

Source: Haematologica, Vol 107, Iss 9 (2022)

Subject Terms: Diseases of the blood and blood-forming organs, RC633-647.5

File Description: electronic resource

Relation: https://haematologica.org/article/view/10494; https://doaj.org/toc/0390-6078; https://doaj.org/toc/1592-8721

Access URL: https://doaj.org/article/de39c8b0aa684d82a347ea24d5b709ac

A cross-trial comparison of single-agent ibrutinib versus chlorambucil-obinutuzumab in previously untreated patients with chronic lymphocytic leukemia or small lymphocytic lymphoma

Authors: Alessandra Tedeschi, Richard Greil, Fatih Demirkan, Tadeusz Robak, Carol Moreno, Paul M. Barr, Bertrand Anz, David Simpson, Gianluca Gaidano, Osnat Bairey, Don Stevens, Devinder Gill, Ian W. Flinn, Thomas J. Kipps, Jan A. Burger, Jennifer Lin, Thomas Webb, Viktor Fedorov, Lori Styles, John G. Gribben

Source: Haematologica, Vol 105, Iss 4 (2020)

Subject Terms: Diseases of the blood and blood-forming organs, RC633-647.5

File Description: electronic resource

Relation: https://haematologica.org/article/view/9357; https://doaj.org/toc/0390-6078; https://doaj.org/toc/1592-8721

Access URL: https://doaj.org/article/06554964b66d40428a91c5679daab744

Combinations of idelalisib with rituximab and/or bendamustine in patients with recurrent indolent non-Hodgkin lymphoma

Authors: Sven de Vos, Nina D. Wagner-Johnston, Steven E. Coutre, Ian W. Flinn, Marshall T. Schreeder, Nathan H. Fowler, Jeff P. Sharman, Ralph V. Boccia, Jacqueline C. Barrientos, Kanti R. Rai, Thomas E. Boyd, Richard R. Furman, Yeonhee Kim, Wayne R. Godfrey, John P. Leonard

Source: Blood Advances, Vol 1, Iss 2, Pp 122-131 (2016)

Subject Terms: Specialties of internal medicine, RC581-951

File Description: electronic resource

Relation: http://www.sciencedirect.com/science/article/pii/S2473952920303785; https://doaj.org/toc/2473-9529

Access URL: https://doaj.org/article/fc19ab6357334e8a83fbb5997926325c

Idelalisib in Combination With Rituximab or Bendamustine or Both in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia

Authors: Steven E. Coutre, Ian W. Flinn, Sven de Vos, Jacqueline C. Barrientos, Marshall T. Schreeder, Nina D. Wagner-Johnson, Jeff P. Sharman, Thomas E. Boyd, Nathan Fowler, Lyndah Dreiling, Yeonhee Kim, Siddhartha Mitra, Kanti Rai, John P. Leonard, Richard R. Furman

Source: HemaSphere, Vol 2, Iss 3 (2018)

Subject Terms: Diseases of the blood and blood-forming organs, RC633-647.5

File Description: electronic resource

Relation: http://journals.lww.com/10.1097/HS9.0000000000000039; https://doaj.org/toc/2572-9241

Access URL: https://doaj.org/article/6da8a4ddda5d45c196dab088c2d15d99

Efficacy and safety of idelalisib in patients with relapsed, rituximab- and alkylating agent-refractory follicular lymphoma: a subgroup analysis of a phase 2 study

Authors: Gilles Salles, Stephen J. Schuster, Sven de Vos, Nina D. Wagner-Johnston, Andreas Viardot, Kristie A. Blum, Christopher R. Flowers, Wojciech J. Jurczak, Ian W. Flinn, Brad S. Kahl, Peter Martin, Yeonhee Kim, Sanatan Shreay, Matthias Will, Bess Sorensen, Madlaina Breuleux, Pier Luigi Zinzani, Ajay K. Gopal

Source: Haematologica, Vol 102, Iss 4 (2017)

Subject Terms: Diseases of the blood and blood-forming organs, RC633-647.5

File Description: electronic resource

Relation: https://haematologica.org/article/view/8055; https://doaj.org/toc/0390-6078; https://doaj.org/toc/1592-8721

Access URL: https://doaj.org/article/659c521f054746b8aea3c4d816e10163